Evidence map›Paper›PMID 35422991›Full record

ArticleJournal of surgical case reports2022

Treatment of in-transit Merkel cell carcinoma by isolated limb infusion with cytotoxic drugs.

Jake J Hindmarch, David J Coker, Richard Waugh, Peter C A Kam, John F Thompson, Robyn P M Saw

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of surgical case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jake J HindmarchMelanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-5706-6903
David J CokerMelanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia.
Richard WaughDepartment of Radiology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
Peter C A KamFaculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
John F ThompsonMelanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia.
Robyn P M SawMelanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia.
The University of Sydney · AURoyal Prince Alfred Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Merkel cell carcinoma of the skin is a rare but aggressive malignancy, which predominantly affects older adults with fair skin. Isolated limb infusion (ILI) using melphalan and actinomycin D was first developed as a minimally invasive treatment option to treat unresectable metastatic melanoma confined to the limb. We report on a 62-year-old male with in-transit metastases (ITMs) treated with ILI to highlight the ongoing role this treatment has when all other therapies have been exhausted. At presentation, the patient had widespread ITMs in the right leg. Positron emission tomography scan demonstrated recurrent disease in the thigh and pelvis, and it was decided to treat the patient with ILI. The patient progressed well in the immediate post-operative period. The patient was able to mobilize from Day 6 post-ILI and was discharged on Day 10. There was an immediate clinical response seen in the lesions, with necrosis developing in the larger lesions.

Identifiers

PMID35422991
PMCPMC9005209
OpenAlexW4223952288

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.